Novartis Stalevo approval in Parkinson’s
Executive Summary
FDA approves Orion/Novartis' Stalevo June 12 for treatment of idiopathic Parkinson's disease. One of Stalevo's indications in labeling is as substitute "for immediate release carbidopa/levodopa and entacapone (Orion/Novartis' Comtan) previously administered as individual products." Stalevo is combination of carbidopa (12.5 mg, 25 mg or 37.5 mg), levodopa (50 mg, 100 mg or 150 mg) and entacapone (200 mg). Labeling suggests easy switch from Comtan 200 mg to the corresponding strength of Stalevo with same amounts of levodopa and carbidopa...